Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks

Metabolism: Clinical and Experimental

Volumn 58, Issue 10, 2009, Pages 1393-1399

  Onat, Altan ^a,b   Can, Günay ^b   Ayhan, Erkan ^c   Kaya, Zekeriya ^d   Hergenç, Gülay ^e  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d Cardiology Department   (Turkey)

^e YILDIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN;

ABDOMINAL OBESITY; ADULT; ARTICLE; CARDIOVASCULAR RISK; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTECTION; RISK ASSESSMENT; SMOKING; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTHROPOMETRY; APOLIPOPROTEINS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CORONARY DISEASE; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS; FEMALE; HUMANS; LIPOPROTEINS, HDL; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES; TURKEY; WAIST-HIP RATIO;

EID: 70249083443     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.05.004     Document Type: Article

References (25)

1. Mackness M.I., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286 (1991) 152-154
2. Garner B., Waldeck A.R., Witting P.K., Rye K.A., and Stocker R. Oxidation of high-density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 273 (1998) 6088-6095
3. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., and Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15 (1995) 1987-1995
4. Wadham C., Albanese N., Roberts J., Wang L., Bagley C.J., Gamble J.R., et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 109 (2004) 2116-2122
5. Epand R.M., Stafford A., Leon B., Lock P.E., Tytler E.M., Segrest J.P., et al. HDL and apolipoproteins A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 14 (1994) 1775-1783
6. Nofer J.R., Levkau B., Wolinska I., Junker R., Fobker M., von Eckardstein A., et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276 (2001) 34480-34485
7. Kontush A., and Chapman M.J. Why is HDL functionally deficient in type 2 diabetes?. Curr Diab Rep 8 (2008) 51-59
8. Ansell B.J., Navab M., Hama S., Kamranpour N., Fonarow G., Hough G., et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108 (2003) 2751-2756
9. Navab M., Ananthramaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., and Fonarow G.C. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45 (2004) 993-1007
10. Andersen R.V., Wittrup H.H., Tybjaerg-Hansen A., Steffensen R., Schnohr P., and Nordestgaard B.G. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease. J Am Coll Cardiol 41 (2003) 1972-1982
11. van der Steeg W.A., Holme I., Boekholdt S.M., Larsen M.L., Lindahl C., Stroes E.S., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 51 (2008) 634-642
12. van Acker B.A.C., Botma G.J., Zwinderman A.H., Koivenhoven J.A., Dallinge-Thie G.M., Sijbrands E.J.G., et al. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesterol ester transfer protein and hepatic lipase gene variants. Atherosclerosis 300 (2008) 161-167
13. Sviridov D., Mukhamedova N., Remalev A.T., Chin-Dusting J., and Nestel P. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 15 (2008) 52-62
14. Onat A., Hergenç G., Bulur S., Uǧur M., Küçükdurmaz Z., and Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol (2009) 10.1016/j.ijcard.2008.12.066 [electronic publication]
15. Onat A., Hergenç G., Can G., and Küçükdurmaz Z. Serum adiponectin confers little protection against diabetes and hypertension in Turkish men. Obesity 17 (2009) 564-570
16. Onat A., Ceyhan K., Başar Ö., Erer B., Toprak S., and Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels-a prospective and cross-sectional evaluation. Atherosclerosis 165 (2002) 285-292
17. Onat A., Avci{dotless} G.Ş., Şenocak M., Örnek E., and Gözükara Y. Plasma lipids and their interrelation in Turkish adults. J Epidem Commun Health 46 (1992) 470-476
18. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus: the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26 (2003) 3160-3167
19. Onat A., Uyarel H., Hergenç G., Karabulut A., Albayrak S., and Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 191 (2007) 182-190
20. Onat A., Hergenç G., and Can G. Prospective validation in identical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition (Turkish). Anadolu Kardiyol Derg 7 (2007) 31-36
21. Rose G.A., Blackburn H., Gillum R.F., and Prineas R.J. Cardiovascular survey methods. 2nd ed (1982), World Health Organization, Geneva 124-127
22. Kontush A., and Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58 (2006) 342-374
23. Ogasawara K., Mashiba S., Hashimoto H., Kojima S., Matsuno S., Takeya M., et al. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apo AI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 397 (2008) 42-47
24. Dodani S., Kaur R., Reddy S., Reed G.L., Navab M., and George V. Can dysfunctional HDL explain high coronary artery disease risk in South Asians?. Int J Cardiol 129 (2008) 125-132
25. Onat A., Hergenç G., Dursunoǧlu D., Küçükdurmaz Z., Bulur S., and Can G. Relatively high levels of serum adiponectin in obese women, a potential indicator of anti-inflammatory dysfunction: relation to sex hormone-binding globulin. Int J Biol Sci 4 (2008) 208-214